These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25484263)

  • 21. Screening for persistent high-risk HPV infections may be a valuable screening method for young women; A retrospective cohort study.
    Ebisch RMF; Ketelaars PJW; van der Sanden WMH; Schmeink CE; Lenselink CH; Siebers AG; Massuger LFAG; Melchers WJG; Bekkers RLM
    PLoS One; 2018; 13(10):e0206219. PubMed ID: 30356297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA methylation markers as a triage test for identification of cervical lesions in a high risk human papillomavirus positive screening cohort.
    van Leeuwen RW; Oštrbenk A; Poljak M; van der Zee AGJ; Schuuring E; Wisman GBA
    Int J Cancer; 2019 Feb; 144(4):746-754. PubMed ID: 30259973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human papillomavirus testing for triage of women with low-grade squamous intraepithelial lesions.
    Cuzick J; Thomas Cox J; Zhang G; Einstein MH; Stoler M; Trupin S; Behrens CM
    Int J Cancer; 2013 Feb; 132(4):959-66. PubMed ID: 22806936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytology-screened referral population.
    Leeman A; Del Pino M; Marimon L; Torné A; Ordi J; Ter Harmsel B; Meijer CJLM; Jenkins D; Van Kemenade FJ; Quint WGV
    Int J Cancer; 2019 Jan; 144(1):160-168. PubMed ID: 30098013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Attributing oncogenic human papillomavirus genotypes to high-grade cervical neoplasia: which type causes the lesion?
    van der Marel J; Berkhof J; Ordi J; Torné A; Del Pino M; van Baars R; Schiffman M; Wentzensen N; Jenkins D; Quint WG
    Am J Surg Pathol; 2015 Apr; 39(4):496-504. PubMed ID: 25353286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands.
    Berkhof J; de Bruijne MC; Zielinski GD; Meijer CJ
    Int J Cancer; 2005 Jun; 115(2):268-75. PubMed ID: 15688404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women.
    Del Mistro A; Frayle H; Ferro A; Callegaro S; Del Sole A; Stomeo A; Cirillo E; Fedato C; Pagni S; Barzon L; Zorzi M;
    J Med Screen; 2014 Mar; 21(1):30-7. PubMed ID: 24488593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg.
    Latsuzbaia A; Hebette G; Fischer M; Arbyn M; Weyers S; Vielh P; Schmitt F; Mossong J
    Diagn Cytopathol; 2017 May; 45(5):384-390. PubMed ID: 28247516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of HPV testing in cervical cancer screening services in Mexico, 2008-2018: a nationwide database study.
    Hurtado-Salgado E; Ortiz-Panozo E; Salmerón J; Saavedra-Lara N; Kuri-Morales P; Pesqueira-Villegas E; Luna-Gordillo R; Franco EL; Lazcano-Ponce E
    Salud Publica Mex; 2018; 60(6):722-733. PubMed ID: 30699277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective cohort study examining cervical cancer screening methods in HIV-positive and HIV-negative Cambodian Women: a comparison of human papilloma virus testing, visualization with acetic acid and digital colposcopy.
    Thay S; Goldstein A; Goldstein LS; Govind V; Lim K; Seang C
    BMJ Open; 2019 Feb; 9(2):e026887. PubMed ID: 30804036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
    Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear.
    Berkhof J; Bulkmans NW; Bleeker MC; Bulk S; Snijders PJ; Voorhorst FJ; Meijer CJ
    Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1268-73. PubMed ID: 16835322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications.
    Rijkaart DC; Berkhof J; van Kemenade FJ; Coupe VM; Rozendaal L; Heideman DA; Verheijen RH; Bulk S; Verweij W; Snijders PJ; Meijer CJ
    Br J Cancer; 2012 Feb; 106(5):975-81. PubMed ID: 22251922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Real-world research on cervical cancer screening program and effect evaluation for Chinese population].
    Zhao YQ; Dai Y; Dang L; Kong LH; Zhang Y; Feng RM; Qiao YL; Lang JH
    Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):764-771. PubMed ID: 30392341
    [No Abstract]   [Full Text] [Related]  

  • 35. Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing.
    Uijterwaal MH; Polman NJ; Van Kemenade FJ; Van Den Haselkamp S; Witte BI; Rijkaart D; Berkhof J; Snijders PJ; Meijer CJ
    Cancer Prev Res (Phila); 2015 Jun; 8(6):502-8. PubMed ID: 25776933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study.
    Ogilvie GS; Krajden M; van Niekerk DJ; Martin RE; Ehlen TG; Ceballos K; Smith LW; Kan L; Cook DA; Peacock S; Stuart GC; Franco EL; Coldman AJ
    Br J Cancer; 2012 Dec; 107(12):1917-24. PubMed ID: 23169286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women, in comparison to genotyping and cytology. Final results of the PIPAVIR study.
    Agorastos T; Chatzistamatiou K; Moysiadis T; Kaufmann AM; Skenderi A; Lekka I; Koch I; Soutschek E; Boecher O; Kilintzis V; Angelidou S; Katsiki E; Hagemann I; Boschetti Gruetzmacher E; Tsertanidou A; Angelis L; Maglaveras N; Jansen-Duerr P
    Int J Cancer; 2017 Aug; 141(3):519-530. PubMed ID: 28470689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.
    Sørbye SW; Fismen S; Gutteberg TJ; Mortensen ES; Skjeldestad FE
    BMJ Open; 2016 Aug; 6(8):e011981. PubMed ID: 27515759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia.
    Simms KT; Hall M; Smith MA; Lew JB; Hughes S; Yuill S; Hammond I; Saville M; Canfell K
    PLoS One; 2017; 12(1):e0163509. PubMed ID: 28095411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs.
    Bais AG; van Kemenade FJ; Berkhof J; Verheijen RH; Snijders PJ; Voorhorst F; Babović M; van Ballegooijen M; Helmerhorst TJ; Meijer CJ
    Int J Cancer; 2007 Apr; 120(7):1505-10. PubMed ID: 17205514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.